Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4573 in Relapsed or Refractory Haematological Malignancies
NCT03263637Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of zemirciclib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and 7 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events up to 12 months, Dose limiting toxicities at 4 weeks and 1 more. Started Oct 2017; status: completed.
02
Drugs
zemirciclib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03263637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263637.